Welcome To The Stem Cell Therapeutics HUB On AGORACOM

Stem Cell is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Stem Cell funds brain injury study, stock rises 27 percent
Reply New Message
Back To Forum List View
Stem Cell funds brain injury study, stock rises
* Approves budget for traumatic brain injury study

* Issues stock options to company directors

* Shares up more than 27 percent

TORONTO, Aug 30 (Reuters) - Stem Cell Therapeutics Corp stock was up more than 27 percent on Monday after the biotechnology company approved funding for a mid-phase clinical study of a treatment for brain injury patients and granted stock options to its directors.

Calgary-based Stem Cell said it will provide the funding to complete the enrollment of 10 traumatic brain injury patients in the study.

The study will be led by Dr. David Zygun of the University of Calgary and will examine the safety of using human chorionic gonadotrophin, a hormone produced during pregnancy, and the anemia drug epoeitin alpha to treat these patients.

A preclinical study showed this therapy helped the brain’s recovery from moderate to serious injuries.

The company, which focuses on central nervous system diseases and specializes in developing treatments that use drugs to stimulate a patient’s stem cells, also announced that it issued 1.55 million stock options to three of its directors at an exercise price of 10 Canadian cents a share, expiring in five years.

Stem Cell Therapeutics, which terminated the positions of its senior executives in June to save money, last week reported a C$2.9 million ($2.7 million) loss for the first six months of this year, partially attributed to higher research and development expenses.

Shares were up 27.3 percent at 7 Canadian cents on the TSX Venture Exchange late on Monday morning.

($1=$1.06 Canadian) (Reporting by Solarina Ho; editing by Peter Galloway)

Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply